AMADIS
29.9.2020 13:57:09 CEST | Business Wire | Press release
Amadis , a payment software and consulting services provider, today announced a streamlined path for North American and international merchants to migrate to the nexo global payment standard, the most comprehensive set of global payment acceptance protocols on the market today. By integrating nexo’s messaging protocols, standards and specifications into its Arkos universal payments acceptance software, Amadis provides “plug-and-play” universal payment software that enables customers to quickly accept new payment types, independent of equipment, technology or geography.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005023/en/
Amadis has helped a diverse range of banking, retail and transport customers deploy nexo-based applications, enabling customers to future-proof their payment systems, while lowering development time and accelerating time to market. With Amadis’ Arkos product, an EMV middleware that manages all the card acceptance processing, customers can rapidly migrate to nexo and vastly reduce their custom development requirements, enabling companies to substantially reduce time to market, risks and costs for each unique payment solution implementation. Arkos can manage any type of equipment (standalone, PINPads, unattended, mobile) and devices while:
- Integrating US processing rules (debit network selection; low value payments)
- Providing central management and reporting
- Meeting M-TIP, ADVT Pre-certified EMV requirements
“By editing the Amadis Arkos software using nexo protocols, we ensure our clients have the same common interoperable interface and protocol across the globe that breeds innovation at the point of contact,” said Emmanuel Haydont, CEO, and co-founder of Amadis. “By using nexo protocols, we help our customers drastically reduce time to market and cost of ownership, while enabling them to free themselves from unnecessary technical dependencies and provide a pathway that better future-proofs merchants as payments continue to evolve.”
nexo standards is the international association enabling global interoperability in payment acceptance. Its membership is expanding rapidly across continents, with members from several countries including the United States, Canada, China, India, Japan, Russia, and Saudi Arabia, further cementing the global interest in its standards and its truly international reach.
Unlike proprietary solutions that lock companies into using proprietary host interfaces, terminal management systems (TMS), platforms or operating in a certain geography, nexo is an open standard that guarantees multiple interoperabilities: cross border, platform, host, market segment and others. nexo standards enables companies to innovate on top of its specifications and protocols, removing both the significant complexity from the technical integration as well as the implementation challenges companies face as they expand acceptance of new payment types from devices in new markets. The nexo association provides open standards and protocols that guarantee cross-border interoperability.
“Market demand for nexo standards is higher than ever before. In response, active members such as Amadis are making significant progress in their deployment and adoption strategies,” comments Jacques Soussana, Secretary-General at nexo standards. “With the combination of our specifications, protocols, implementation guidelines, collaborative working groups, and testing and certification support, we are providing members with the tools to build and validate their solutions, fast-tracking their path to deployment. The global adoption of nexo standards is fast becoming a reality.”
Amadis’ global customers require payment acceptance solutions that are secure and ensure optimized operations, while allowing for best management of future-proofing needs in the near and long-term. nexo standards is the international association enabling global interoperability in payment acceptance. With the recent global stresses the economy and industries have faced, it has become imperative that solution providers seek out standards such as nexo that allow businesses to operate more efficiently and expand globally.
*EMV ® is a registered trademark in the U.S. and other countries and an unregistered trademark elsewhere. The EMV trademark is owned by EMVCo, LLC
About Amadis
Amadis is a privately-held division of Maxim Integrated. Amadis is a leader in payment software technology, with its software running on more than 10 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment processing options using custom or commercially available technology, independent of hardware or geography. The company brings an elite, experienced software team to the industry and enables solutions for international merchants in over 23 countries. Learn more at www.amadis.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005023/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
